REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

16 May 2024 08:00:00 By Nasdaq GlobeNewswire

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

07 Apr 2024 17:00:00 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

26 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

06 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune to Present at Three Upcoming Investor Conferences

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

08 Feb 2024 08:00:01 By Nasdaq GlobeNewswire

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

28 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

05 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

08 Nov 2023 09:10:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

07 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

03 Nov 2023 19:30:00 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

19 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

03 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Replimune Announces Sander Slootweg will Depart from its Board of Directors

20 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

06 Jun 2023 10:00:00 By Nasdaq GlobeNewswire

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

05 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

03 Jun 2023 14:15:00 By Nasdaq GlobeNewswire